Skip to main content
Accessibility|Contact|Privacy|Terms of Service

Fibromyalgia Treatment Effective at Reducing Pain and Symptoms Shows Promise

  • Published: 2014-11-20 : Author: Innovative Med Concepts, LLC : Contact: www.innovativemedconcepts.com
  • Synopsis: IMC-1 oral medication proves highly effective at reducing pain and other symptoms of fibromyalgia (FM) in patients in a recent clinical trial.

Main Document

"Fibromyalgia is a multi-symptom disorder involving widespread pain, fatigue, headaches, sleep problems, mood changes and inability to concentrate."

Detailed results of the randomized, double-blinded, placebo-controlled Phase II study, known as PRID-201, were presented today at the 2014 American College of Rheumatology annual meeting in Boston by William L. Pridgen, M.D., FACS, founder and CEO of Innovative Med Concepts.

According to Daniel J. Clauw, M.D., director of the Chronic Pain & Fatigue Research Center at the University of Michigan (Ann Arbor), commenting on the PRID-201 results, "IMC-1 shows promise as a potentially new treatment for the millions of people who suffer from this debilitating condition."

IMC-1 is a novel combination oral medicine designed to treat HSV-1, a condition that may be one of the underlying causes of fibromyalgia syndrome. IMC-1 combines the anti-herpes virus nucleoside analog famciclovir with anti-herpes virus activity exhibited by the COX-2 inhibitor celecoxib.

Fibromyalgia is a multi-symptom disorder involving widespread pain, fatigue, headaches, sleep problems, mood changes and inability to concentrate. Its causes are unknown. According to the National Fibromyalgia Association, an estimated 3-6 percent of people worldwide suffer from the condition - 10 million people in the United States alone.

The 16-week study evaluated the efficacy and safety of IMC-1, a fixed-dose-combination of famciclovir and celecoxib. 143 FM patients were recruited at 12 U.S. clinics. Patients received either a combination treatment of IMC-1 or a matching placebo.

According to Dr. Pridgen, chronic tissue-resident herpes virus may be an underlying cause of fibromyalgia. IMC-1 represents a novel treatment by combining an anti-herpes virus nucleoside analog with the anti-herpes virus activity exhibited by a COX-2 inhibitor.

"Many herpes viruses are known to significantly upregulate COX enzymes in the body, which in turn are important for efficient viral replication," Pridgen said. "In theory, physical or emotional stress in patients can reactivate the virus and result in perpetuation of the symptoms of fibromyalgia. Effectively suppressing latent viruses may significantly improve the pain and related symptoms of FM."

The PRID-201 clinical study tested this hypothesis using the IMC-1 fixed-dose-combination. Patients in the trial rated their pain over the course of the study using a 0-10 numeric rating scale, with the study's primary endpoint being the reduction in average pain from baseline to week 16. Pain measured on both a 24-hour and seven-day recall basis met statistical significance, with the seven-day recall data achieving high statistical significance (p=0.001). Other therapeutic domains studied that showed statistical significance were Patient Global Impression (PGIC), all three Revised Fibromyalgia Impact Questionnaire (FIQ-R) domains, 30% and 50% Pain reduction responder analysis and the NIH PROMIS fatigue instrument.

Other noteworthy results from PRID-201:

"Compared to placebo, the relatively high completion rate, improved pain scores and the low rate of discontinuation because of adverse events are consistent with a well-tolerated and effective therapy," Dr. Clauw said.

Innovative Med Concepts, LLC, is a biotech company developing novel treatments for fibromyalgia, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), irritable bowel syndrome and other related conditions. On the Web: innovativemedconcepts.com

Similar Topics

1 : Intensity Therapeutics Human Cancer Clinical Trial Update : Intensity Therapeutics, Inc..
2 : Fighting My Cancer as Much as Possible - Why Many Patients Join Phase 1 Clinical Trials : European Society for Medical Oncology.
3 : Pediatric Neural Tumor Shrinkage Shown in Selumetinib Clinical Trial : NIH/National Cancer Institute.
4 : Antidote: A Digital Health Company on a Mission : Grace McElroy Head of Partnerships and Distribution, TrialReach.
5 : Evaluating FDA Approach to Cancer Clinical Trials : Richard Pazdur, M.D..
From our Clinical Trials section - Full List (73 Items)


Submit disability news, coming events, as well as assistive technology product news and reviews.


Loan Information for low income singles, families, seniors and disabled. Includes home, vehicle and personal loans.


Famous People with Disabilities - Well known people with disabilities and conditions who contributed to society.


List of awareness ribbon colors and their meaning. Also see our calendar of awareness dates.


Blood Pressure Chart - What should your blood pressure be, and information on blood group types/compatibility.





1 : Teaching Baby Sign Language - Nita, Show Us More
2 : MitoQ Novel Antioxidant Makes Old Arteries Seem Young Again
3 : Telemedicine Helps Overcome Healthcare Gender Based Barriers
4 : Screen Reader Plus Keyboard Helps Blind, Low-Vision Users Browse Modern Webpages
5 : Our Digital Remains Should be Treated with Same Care and Respect as Physical Remains
6 : Tungsten: Concern Over Possible Health Risk by Human Exposure to Tungsten
7 : Student Loan Discharge Process for Disabled Veterans Made Easier
8 : Growing Bone and Cartilage Tissues for Humans from Flaxseed Like Particles


Disclaimer: This site does not employ and is not overseen by medical professionals. Content on Disabled World is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. See our Terms of Service for more information.

Reporting Errors: Disabled World is an independent website, your assistance in reporting outdated or inaccurate information is appreciated. If you find an error please let us know.

© 2004 - 2018 Disabled World™